Cell Line Data Sheet for TC-71

Disease:	Ewing's Sarcoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease)
Treatment:	
Disease Stage:	
Gender:	Male
Age at diagnosis:	22 years
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Solid tumor (humerus)
Primary Tumor Site:	
Date Established:	1981
EWS/FLI1 Status:	ERG
p53 functionality:	Non-Functional
Karyotype:	-Y,8,t(1;7)(q25;p11),del(2)(q36),t(2;14)(q12;q32)3q+,?5,del(6)(q26),del(7)(q31),t(7;11)(q21;q23), t(8;14) (q11;p11),t(11;22)(q24;q12)
Modal No:	76,80 (65-84)

IC90 (DIMSCAN*):

VNC (ng/ml)	L-PAM (µg/ml)	ETOP (ng/ml)	RAP (ng/ml)
0.34 ± 0.02	3.22 ± 0.25	0.15 ± 0.01	N/A

VNC, vincristine; L-PAM, melphalan; ETOP, etoposide; RAP, rapamycin

Growth Conditions: Please see Protocols section at https://www.cccells.org/protocols.php
5% CO_2, 20% O_2, 37.0°C

Media Formulation: Please see Protocols section at https://www.cccells.org/protocols.php
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time:	24 hours
Growth Properties:	Teardrop-shaped cells with processes, adherent, grow mostly in clumps
STR Profile:	May be obtained at https://strdb.cccells.org/

Notes:

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for TC-71

References:

1. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. Clin Cancer Res. 6, 551-558, 2000. PubMed ID: 10690538
https://clincancerres.aacrjournals.org/content/6/2/551.long

2. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64: 5415-5424, 2004. PubMed ID: 15289350
https://cancerres.aacrjournals.org/content/64/15/5415.long

3. Whang-Peng, J., Triche, T.J., Knutsen, T., Miser, J., Kao-Shan, S., Tsai, S., and Israel, M. A. (1986). Cytogenetic Characterization of Selected Small Round Cell Tumors of Childhood. Cancer Genet Cytogene 21: 185-208. PubMed ID: 3004699
https://www.sciencedirect.com/science/article/pii/0165460886900014?via%3Dihub

4. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr Blood Cancer 56: 239-249, 2011. PubMed ID: 20922763
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

SEE NCI Pediatric Preclinical Testing Program references.

Cell Line Data Sheet for TC-71

Cell Line Name: **TC-71**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)